![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
High Efficacy of Sofosbuvir/Velpatasvir In HCV Genotypes 1-6 Infected Patients With Cirrhosis: Pooled Data From the ASTRAL 1, 2 and 3 Trials
|
|
|
Reported by jules Levin
HEPDART 2015, December 6-10, 2015, Wailea, Hawaii
T Asselah1*, M Sulkowski2, IM Jacobson3, T Morgan4, B Conway5, S Gordon6, ES Svarovskaia7, L Liu7, J McNally7, A Osinusi7, DM Brainard7, JG McHutchison7, JJ Feld8, GR Foster9
1University Paris Diderot, INSERM U773, Paris, France; 2Johns Hopkins University, Baltimore, US; 3Mount Sinai Beth Israel Medical Center, New York, US; 4VA Long Beach Healthcare System , Long Beach, US; 5Vancouver Infectious Diseases Centre, Vancouver, BC, Canada; 6Henry Ford Health System, Detroit, US; 7Gilead Sciences Inc., Foster City, US; 8Toronto Western Hospital Liver Centre, Toronto, Canada ; 9Queen Mary University of London, London
AASLD: Sofosbuvir+GS-5816 GT 1-6: ASTRAL-1, ASTRAL-2, ASTRAL-3, ASTRAL-4 - (12/09/15)
Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection - (12/11/15)
![HepDart1.gif](../images/121415/121415-8/HepDart1.gif)
![HepDart2.gif](../images/121415/121415-8/HepDart2.gif)
![HepDart3.gif](../images/121415/121415-8/HepDart3.gif)
![HepDart4.gif](../images/121415/121415-8/HepDart4.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|